Liquidmetal Technologies Bets Big on In-House Manufacturing

Liquidmetal Technologies Inc ((LQMT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Liquidmetal Technologies Inc.’s latest earnings call struck a cautiously optimistic tone, blending ambitious strategic moves with stark near-term financial strain. Management highlighted a strong cash cushion, new manufacturing and IP initiatives and promising early customer traction, yet investors were reminded that revenue remains minimal and losses are large, making execution over the next two years critical.

Cash Position Provides Strategic Runway

Liquidmetal ended fiscal 2025 with roughly $20 million of liquid cash and investments, giving the company meaningful runway to pursue its manufacturing buildout and commercialization plans. Management stressed that there are no going-concern issues, signaling confidence that current resources are sufficient to fund operations and growth initiatives in the near term.

Shift to In-House Manufacturing in Hangzhou

A central theme was the strategic pivot from a fully outsourced model to in-house manufacturing at a new plant in Hangzhou. The facility is being developed to bring production closer to the company’s technology, and management expects it to be operational around 2026, positioning Liquidmetal to better control quality, costs and customer delivery.

Liquid Morphium Platform and IP Strategy

Liquidmetal introduced its “Liquid Morphium” advanced injection molding machine as a cornerstone of its future manufacturing approach. The company also formed Liquid Morphium LLC as an IP holding vehicle to capture process and tooling innovations, aiming to build a defensible portfolio that can support higher-margin business and potential licensing opportunities over time.

Leadership Focused on Scaling Operations

Professor Lugee Li has been appointed to lead Asia operations and is now fully dedicated to Liquidmetal’s growth efforts. Drawing on his manufacturing experience and network, including his background at Eontec, Li is expected to drive the ramp-up of the Hangzhou plant and coordinate with collaborators to accelerate commercialization.

Early Customer Traction in Mobile and Medical

Management pointed to early signs of market traction, including completed prototypes for a top-tier mobile device company and active production orders in the medical device segment. An outsourced partner, Yeehaw, has also reached tier-one vendor status with a global mobile device player and with mobile brands in China, supporting Liquidmetal’s push into high-volume consumer markets.

Hidden Value in Corporate Real Estate

Beyond its cash holdings, the company highlighted potential upside from its corporate real estate. The corporate office carries a book value of $7 million, while management believes its market value is more than double that figure, suggesting additional collateral or liquidity that could be tapped if needed to support growth or manage risk.

Strategic Rationale for Manufacturing Investment

Management laid out a clear logic for bringing manufacturing in-house, emphasizing the ability to generate proprietary IP and improve unit economics at scale. By owning more of the process, Liquidmetal aims to lift gross margins and become a more attractive partner to tier-one manufacturers seeking differentiated materials and precision components.

Revenue Still Very Limited

The financial picture remains challenging, with fiscal 2025 revenue at only about $800,000, far below the ambition of becoming a meaningful advanced materials supplier. This low sales base underscores how early the commercialization effort still is and leaves little room for operational missteps as the company ramps spending.

Net Loss Highlights Scale of Investment

Liquidmetal reported a net loss of roughly $2.4 million for 2025, equal to about 300% of its annual revenue. The mismatch between current income and expenses underscores that the business is still in investment mode, and profitability remains a distant goal dependent on significant growth in customer adoption.

Negative EBITDA Signals Ongoing Cash Burn

EBITDA for the year came in around negative $1.8 million, or roughly 225% of revenue, signaling ongoing operating cash burn relative to today’s limited scale. While the strong balance sheet cushions this, the company will need to deliver meaningful top-line growth as its manufacturing footprint and overhead expand.

Capex and Execution Risks in Hangzhou Buildout

The move to in-house production brings higher upfront capital expenditures and considerable execution risk as the Hangzhou plant is constructed and ramped. With the facility not yet operational, investors face timing uncertainty around when meaningful volume, cost efficiencies and margin benefits will actually materialize.

Adoption and Concentration Risks in Target Markets

Liquidmetal’s success will depend on broader market adoption among tier-one customers in areas like foldable phone hinges and emerging “physical AI” applications. Management acknowledged that, given the company’s historical lack of manufacturing know-how and reliance on a few key relationships, concentration and adoption risks remain material.

Forward-Looking Guidance and Outlook

Looking ahead, management expects the Hangzhou plant to be fully operational toward 2026 and is prepared for elevated near-term capex in exchange for better unit economics and higher gross margins. They are banking on new IP from the Liquid Morphium platform, prototypes with top-tier mobile customers, medical production orders and tier-one collaborations to drive future revenue growth, supported by a strong cash and real estate base.

Liquidmetal Technologies’ earnings call painted a picture of a company in transition, fortified by cash and assets but still searching for scale. If the Hangzhou buildout, Liquid Morphium platform and early customer wins translate into sustained orders, the upside could be meaningful, yet for now investors must weigh that potential against low revenues, persistent losses and real execution risk.